The VAD BestBeat by NewCorTec has been implanted in a human body for the first time, and clinical trials have started. This represents an important goal for the Umbra Group: providing state-of-the-art technology in the field of linear movement for a biomedical device which will play a significant role in treating serious heart disorders.

Over the last few years, this has been the driving force enabling us to focus our attention on hi-tech projects with courage and determination

The results of research and development in the aerospace field which began in the early 1990s have been transferred by our engineers and technicians to the biomedical field. The key element for the movement in the VAD BestBeat is a ballscrew of the same type and generation as those which have made their mark – for reliability and robustness – in the most demanding aeronautical and industrial applications.

This opens up new prospects for the application of our product – an exciting challenge for all of us. At the same time, we can safely say that laboratory tests and the performance of many thousands of similar devices in the field, mean that the application of the VAD BestBeat is absolutely reliable today.

http://www.newcortec.com/

COMUNICATion_newCortec_ ING.doc

Press Release: First made-in-Italy transplant of an artificial heart